WELLBUTRIN SR Rx
Generic Name and Formulations:
Bupropion HCl 100mg, 150mg, 200mg; sust-rel tabs.
Indications for WELLBUTRIN SR:
Major depressive disorder (MDD).
Swallow whole. Avoid bedtime dosing. ≥18yrs: initially 150mg once daily in the AM for at least 3 days; if tolerated, increase to 150mg twice daily at least 8hrs apart. May increase after several weeks to max 200mg twice daily at least 8hrs apart. Moderate-to-severe hepatic impairment: max 100mg/day or 150mg every other day. Renal or mild hepatic impairment: consider reduced dose and/or dose frequency. Switching to Wellbutrin XL: give same total daily dose.
<18yrs: not established.
Seizure disorders. Bulimia. Anorexia nervosa. During or within 14 days of discontinuing MAOIs. Concomitant linezolid or IV methylene blue. Abrupt withdrawal of alcohol, benzodiazepines, barbiturates, or antiepileptics. Other forms of bupropion (eg, Zyban).
Not for treating bipolar depression or for smoking cessation. Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor all patients for clinical worsening or unusual behavioral changes. Monitor for neuropsychiatric adverse events (eg, behavioral changes, agitation, depression, suicidal ideation); evaluate and consider treatment continuation under closer monitoring, or discontinuation if occur. Pre-existing psychiatric disorders. Bipolar disorder. Mania/hypomania. Psychosis. Risk of seizures; discontinue if seizure occurs: do not restart. Angle-closure glaucoma. Unstable heart disease. CHF. Recent MI. Monitor BP before initiating and periodically during treatment. Hepatic or renal impairment (monitor closely). Reevaluate periodically. Maintain at lowest effective dose. Write ℞ for smallest practical amount. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Do not start with concomitant linezolid or IV methylene blue; if treatment necessary, discontinue bupropion before starting. Monitor for 2 weeks or until 24hrs after last dose of linezolid or IV methylene blue, whichever comes first. Avoid alcohol. Levodopa, amantadine may increase CNS toxicity. Caution with drugs that lower seizure threshold (eg, theophylline, antidiabetics, anorectics, CNS stimulants, systemic steroids, tricyclic antidepressants, antipsychotics) or factors that lower seizure threshold (eg, opiate or cocaine addiction, excessive use of alcohol or sedatives). Caution with CYP2B6 inhibitors (eg, ticlopidine, clopidogrel) or drugs metabolized by CYP2D6 including antidepressants (eg, venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (eg, haloperidol, risperidone, thioridazine), β-blockers (eg, metoprolol), Class 1C antiarrhythmics (eg, propafenone, flecainide); consider dose reduction. Caution with CYP2B6 inducers (eg, ritonavir, lopinavir, efavirenz, carbamazepine, phenobarbital, phenytoin), tamoxifen; consider dose increase. May antagonize digoxin; monitor. May cause false (+) urine immunoassay test results for amphetamine.
Dry mouth, nausea, insomnia, dizziness, pharyngitis, abdominal pain, agitation, anxiety, tremor, palpitation, sweating, tinnitus, myalgia, anorexia, urinary frequency, rash (rarely may be serious, eg, erythema multiforme, Stevens-Johnson syndrome), headache, blurred vision, tachycardia; hypertension.
XL tabs 150mg—30, 90; 300mg—30; SR tabs—60; Tabs—contact supplier
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Predicting Seizure Risk Following Ischemic Stroke With SeLECT Score
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Exome-Targeted Capture Sequencing Can Diagnose Previously-Undetected Ataxia
- Strategies for Preventing and Treating Delirium
- High Total Cholesterol Neuroprotective Against Cognitive Decline